PIK3CA H1047R and inavolisib — the mutant-selective degrader story

PIK3CA is the most frequently mutated oncogene in hormone receptor–positive breast cancer, and for fifteen years the field tried to drug it with isoform-selective inhibitors that worked just well enough to be approved and just poorly enough to be disappointing. Inavolisib changes the shape of that story. It is the first PI3K alpha–targeting agent designed not just to block the mutant enzyme but to degrade it. The FDA approval in October 2024 and the INAVO120 phase 3 readout give the cleanest validation yet that you can selectively kill a mutant protein in the clinic without wrecking the wild-type isoform.

Two hotspots, two different mechanisms

About 80% of PIK3CA mutations in cancer fall into two hotspots, and they activate p110 alpha by completely different structural routes. Understanding this is the difference between picking the right inhibitor chemistry and picking the wrong one.

• H1047R sits in the kinase domain near the C-terminus. The wild-type histidine at 1047 helps the C-terminal tail fold back against the catalytic core in an auto-inhibited conformation; mutating it to arginine abolishes that auto-inhibition, opens the membrane-binding face of the enzyme, and increases affinity for anionic phospholipid head groups. The mutant is essentially always docked on the membrane where its substrate PIP2 lives.
• E542K and E545K sit in the helical domain. The wild-type glutamates make salt bridges with lysine residues on the nSH2 regulatory subunit, which keeps p110 alpha inhibited until a phosphotyrosine peptide displaces nSH2. The charge-reversal mutation (glutamate to lysine) breaks that salt bridge directly — the inhibitory contact is gone whether or not a tyrosine kinase has fired upstream.

Both routes converge on constitutive PI3K alpha activation, but the conformations are different, and that matters for drug binding. Compounds optimized against the H1047R kinase domain are not automatically the best fit for helical-domain mutants, and vice versa. Most modern inhibitors aim for the ATP-binding cleft, where the geometry is more conserved.

Alpelisib: the proof of concept

Alpelisib (Piqray) was the first PI3K alpha–selective inhibitor to clear the FDA, approved in 2019 for HR+/HER2− advanced breast cancer with a PIK3CA mutation, in combination with fulvestrant. The SOLAR-1 trial showed a roughly doubled progression-free survival in the mutant population (11.0 vs 5.7 months) but no benefit in the wild-type cohort — the predictive biomarker is the mutation, not the disease.

The clinical experience also exposed the on-target toxicity that haunts the whole PI3K class: hyperglycemia. PI3K alpha sits at the heart of insulin signaling in skeletal muscle and adipose tissue, so inhibiting it systemically blunts the post-prandial insulin response. Severe hyperglycemia led to dose reductions or discontinuations in a sizeable fraction of SOLAR-1 patients, which set the bar for the next generation: same antitumor effect, less metabolic damage. The way to get there was either better isoform selectivity or better mutant-versus-wild-type selectivity.

Inavolisib: degrade, do not just inhibit

Inavolisib (Itovebi, Genentech) is a highly selective p110 alpha inhibitor with a second, more interesting property: it accelerates the degradation of mutant p110 alpha while sparing the wild-type protein. The mechanism appears to involve trapping the mutant enzyme in a conformation that is recognized by the cellular protein quality-control machinery, so the drug both blocks catalysis and reduces the steady-state level of the oncogenic protein. The functional consequence is that inavolisib achieves deeper pathway suppression at lower systemic exposure, and the wild-type alpha activity that runs insulin signaling is less affected.

That mechanism showed up in the INAVO120 phase 3 trial. First-line inavolisib added to palbociclib and fulvestrant in PIK3CA-mutated, HR+/HER2− endocrine-resistant advanced breast cancer doubled the progression-free survival (15.0 vs 7.3 months, hazard ratio 0.43) and improved overall survival to 34.0 months versus 27.0 months in the control arm. The FDA approval on October 10, 2024 covers the triplet in this exact setting.

What is still hard

Hyperglycemia did not disappear with inavolisib, and the full PI3K–mTOR–AKT pathway still has many bypass options once it is pressured. Combinations are the ongoing story: PI3K alpha plus CDK4/6 plus endocrine therapy is now the validated triplet, and the next questions are what to add for ESR1-mutant patients, and how to sequence against the inevitable resistance. Resistance pathways already characterized include PTEN loss (which reactivates downstream PI3K signaling regardless of p110 alpha activity) and AKT1 E17K. The selectivity of inavolisib for the mutant protein also raises the question of whether the same degrader logic extends to other PIK3CA mutations beyond H1047R, particularly the helical-domain hotspots where the induced conformation may differ.

Try the docking yourself

The canonical PI3K alpha H1047R structure with a mutant-selective inhibitor bound is 4JPS — H1047R in the open membrane-binding conformation. Open Studio and pick PI3K alpha from the target catalog with H1047R from the mutation chips to dock your own ligands against the mutant ATP pocket. Liganx renders both the wild-type and H1047R receptors side-by-side so you can see the selectivity story directly — the differential ATP-pocket geometry around the C-terminal tail is what gives mutant-selective compounds their handle.

Liganx is molecular docking online: free, browser-based, and set up for exactly this kind of mutation question. If you want to try molecular docking on PIK3CA H1047R without a local install, that is the fastest path.

Primary sources

• Jhaveri KL, Im SA, Saura C, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. NEJM 391(17), 1584–1596 (2024). doi:10.1056/NEJMoa2404625
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. NEJM 380, 1929–1940 (2019). doi:10.1056/NEJMoa1813904
• Burke JE, Perisic O, Masson GR, et al. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 alpha (PIK3CA). PNAS 109, 15259–15264 (2012). doi:10.1073/pnas.1205508109
• FDA. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer. October 10, 2024. FDA.gov